Early Phase Clinical Research Support

项目摘要(见说明)：早期临床研究支持(EPCRS)的目的是提供资金，支持来自梅奥临床癌症中心(MCCC)科学研究人员的短期、试点和I期临床研究。这一资源的主要功能是鼓励开发新的预防、诊断、检测和治疗策略。因此，对有希望的想法的支持将继续得到支持，这些想法可以导致更明确的试验和资助赠款。 Steven Alberts博士提供EPCRS的总体指导和监督；Jann Sarkaria博士是早期临床研究委员会的主席。对所有要求EPCRS支持的拟议研究进行评估，以确保符合CCSG指南定义的资格标准。除了个人的科学价值，拟议的研究还评估了未来与现有的和正在开发的MCCC计划的潜在交叉点，以及外部资金的潜力。 EPCRS支持包括研究协调和研究新药(IND)管理。研究协调包括参与者试验管理支持，以识别、招募参与者并将其纳入研究，以及数据编辑和跟踪。IND申请支持包括对所有IND申请的监管协助和管理，以及EPCRS批准的研究的进度报告。

PROJECT SUMMARY (See instructions): The purpose of Early Phase Clinical Research Support (EPCRS) is to provide funding to support short-term, pilot, and phase I clinical research studies which originate from Mayo Clinic Cancer Center (MCCC) scientific investigators. The primary function of this resource is to encourage the development of novel prevention, diagnostic, detection, and treatment strategies. Therefore, support of promising ideas which can lead to more definitive trials and funded grants will continue to be supported. Dr. Steven Alberts provides overall direction and oversight of the EPCRS; Dr. Jann Sarkaria is the chair of the Early Phase Clinical Research Committee. All proposed studies requesting EPCRS support are assessed to ensure eligibility criteria as defined by the CCSG guidelines. In addition to individual scientific merit, proposed studies are assessed for potential future intersections with existing and developing MCCC programs, as well as potential for extramural funding. EPCRS support includes study coordination and Investigational New Drug (IND) management. Study coordination includes participant trial management support to identify, recruit, and enter participants onto study as well as data editing and tracking. IND application support includes regulatory assistance and management for all IND applications and progress reports for EPCRS approved studies.